Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Morris

Showing results (171-180 of 207) with videos related to

Pageof 21
Sort By:
Health Physics|February 25, 2014
Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancerLawrence T Dauer, Matthew J Williamson, John Humm, et al.
Annals of Surgery|May 16, 2013
Burn injury enhances bone formation in heterotopic ossification modelJonathan R Peterson, Sara De La Rosa, Hongli Sun, et al.
Pharmaceutical Research|March 20, 2014
Biorelevant in vitro performance testing of orally administered dosage forms-workshop reportChristos Reppas, Horst-Dieter Friedel, Amy R Barker, et al.
AAPS Pharmscitech|June 21, 2011
FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage formsCynthia K Brown, Horst Dieter Friedel, Amy R Barker, et al.
Blood Advances|June 17, 2024
Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19Dolores Grosso, John L Wagner, Allyson O'Connor, et al.
Journal of Pharmaceutical Sciences|August 28, 2018
FIP Guidelines for Dissolution Testing of Solid Oral ProductsHorst Dieter Friedel, Cynthia K Brown, Amy R Barker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
Pediatric Research|July 24, 2023
Outcomes by disease onset, sex, and intervention in neonates with SIP and surgical NECParvesh Mohan Garg, Katheryn Lett, Md Abu Yusuf Ansari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 6, 2004
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancerSteven M Larson, Michael Morris, Ilonka Gunther, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Pageof 21

Showing results (171-180 of 207) with videos related to

Sort By:
Pageof 21
Health Physics|February 25, 2014
Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancerLawrence T Dauer, Matthew J Williamson, John Humm, et al.
Annals of Surgery|May 16, 2013
Burn injury enhances bone formation in heterotopic ossification modelJonathan R Peterson, Sara De La Rosa, Hongli Sun, et al.
Pharmaceutical Research|March 20, 2014
Biorelevant in vitro performance testing of orally administered dosage forms-workshop reportChristos Reppas, Horst-Dieter Friedel, Amy R Barker, et al.
AAPS Pharmscitech|June 21, 2011
FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage formsCynthia K Brown, Horst Dieter Friedel, Amy R Barker, et al.
Blood Advances|June 17, 2024
Safety and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19Dolores Grosso, John L Wagner, Allyson O'Connor, et al.
Journal of Pharmaceutical Sciences|August 28, 2018
FIP Guidelines for Dissolution Testing of Solid Oral ProductsHorst Dieter Friedel, Cynthia K Brown, Amy R Barker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
Pediatric Research|July 24, 2023
Outcomes by disease onset, sex, and intervention in neonates with SIP and surgical NECParvesh Mohan Garg, Katheryn Lett, Md Abu Yusuf Ansari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 6, 2004
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancerSteven M Larson, Michael Morris, Ilonka Gunther, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)Matthew R Smith, Susan Halabi, Charles J Ryan, et al.
Pageof 21